Edition:
United States

DiaSorin SpA (DIAS.MI)

DIAS.MI on Milan Stock Exchange

101.30EUR
19 Jul 2019
Change (% chg)

€-1.20 (-1.17%)
Prev Close
€102.50
Open
€102.60
Day's High
€103.10
Day's Low
€100.80
Volume
64,496
Avg. Vol
118,900
52-wk High
€107.40
52-wk Low
€68.60

Latest Key Developments (Source: Significant Developments)

Diasorin And Qiagen Expand Collaboration For QuantiFERON Technology
Wednesday, 5 Jun 2019 01:25am EDT 

June 5 (Reuters) - DiaSorin SpA ::SAYS DIASORIN AND QIAGEN ANNOUNCE EXPANSION OF COLLABORATION FOR QUANTIFERON TECHNOLOGY.NEW TEST BASED ON QUANTIFERON TECHNOLOGY FOR DIAGNOSIS OF LYME DISEASE WILL BE USED ON LIAISON PLATFORMS.  Full Article

Diasorin Launches Elastasi-1 Test For Diagnosis Of Chronic Exocrine Pancreatitis On Liaison Xl
Monday, 6 May 2019 09:16am EDT 

May 6 (Reuters) - DiaSorin SpA ::LAUNCHES ELASTASI-1 TEST FOR DIAGNOSIS OF CHRONIC EXOCRINE PANCREATITIS ON LIAISON XL.  Full Article

DiaSorin Launches Molecular Test Simplexa Bordetella Direct In U.S. Market
Thursday, 3 Jan 2019 07:20am EST 

Jan 3 (Reuters) - DiaSorin SpA ::LAUNCHES MOLECULAR TEST SIMPLEXA BORDETELLA DIRECT IN U.S. MARKET.  Full Article

DiaSorin Launches Molecular Test To Detect Group B Strep On U.S. Market
Monday, 19 Nov 2018 09:07am EST 

Nov 19 (Reuters) - DiaSorin SpA ::LAUNCHES MOLECULAR TEST TO DETECT GROUP B STREP ON U.S. MARKET.  Full Article

Diasorin sees potential negative impact from Iran, contracts delay
Wednesday, 7 Nov 2018 09:49am EST 

Nov 7 (Reuters) - DiaSorin CEO Carlo Rosa says::2018 GUIDANCE COULD BE NEGATIVELY IMPACTED BY IRAN AND DELAY IN CONTRACTS.  Full Article

Diasorin CEO expects vitamin D volumes in US to fall 20 pct over next 12 mths
Wednesday, 7 Nov 2018 09:01am EST 

Nov 7 (Reuters) - DiaSorin CEO Carlo Rosa says::EXPECTS 20 PERCENT FALL IN VITAMIN D VOLUMES IN THE US MARKET OVER NEXT 12 MONTHS.  Full Article

DiaSorin Q3 Net Profit Up At EUR 35.9 Mln
Wednesday, 7 Nov 2018 07:02am EST 

Nov 7 (Reuters) - DiaSorin SpA ::Q3 NET PROFIT EUR 35.9 MILLION VERSUS EUR 29.3 MILLION YEAR AGO.Q3 REVENUE EUR 162.8 MILLION VERSUS EUR 149.4 MILLION YEAR AGO.  Full Article

Diasorin SpA Receives CE Marking For Its New Simplexa VZV Direct assay
Friday, 12 Oct 2018 08:33am EDT 

Oct 12 (Reuters) - DiaSorin SpA ::ANNOUNCED TO HAVE RECEIVED CE MARKING FOR ITS NEW SIMPLEXA VZV DIRECT ASSAY.  Full Article

Diasorin Launches New Liaison Quantiferon-TB Gold Plus In Partnership With Qiagen
Monday, 17 Sep 2018 01:27am EDT 

Sept 17 (Reuters) - Diasorin Spa ::LAUNCHES NEW LIAISON QUANTIFERON-TB GOLD PLUS ASSAY AS AN AID FOR LATENT TUBERCULOSIS DETECTION IN PARTNERSHIP WITH QIAGEN.SAYS TEST WAS DEVELOPED IN A PARTNERSHIP BETWEEN DIASORIN AND QIAGEN.SAYS TEST WILL BE LAUNCHED IN U.S. BY 2019 AND IN CHINA BY 2020.  Full Article

DiaSorin Q1 Net Profit Up At EUR 38.3 Mln
Tuesday, 8 May 2018 06:29am EDT 

May 8 (Reuters) - DiaSorin SpA ::Q1 REVENUE EUR 164.5 MILLION VERSUS EUR 157.5 MILLION YEAR AGO.Q1 NET PROFIT EUR 38.3 MILLION VERSUS EUR 32.9 MILLION YEAR AGO.SEES 2018 REVENUES GROWTH OF ABOUT 11 PERCENT AT CER (CONSTANT CURRENCIES) COMPARED TO THE 2017 FINANCIAL YEAR.SEES 2018 EBITDA GROWTH OF ABOUT 13 PERCENT AT CER (CONSTANT CURRENCIES) COMPARED TO THE 2017 FINANCIAL YEAR.  Full Article

CORRECTED-DIARY - Italy to June 30

(Changes dates of two-day energy conference in Rome to May 29-30 from May 28-29) Inclusion of diary items does not necessarily mean that Reuters will file a story based on the event.